Neeta Somaiah, MD

Peer-Reviewed Articles

1. Guadagnolo BA, Bassett RL, Mitra D, Farooqi A, Hempel C, Dorber C, Willis T, Wang WL, Ratan R, Somaiah N, Benjamin RS, Torres KE, Hunt KK, Scally CP, Keung EZ, Satcher RL, Bird JE, Lin PP, Moon BS, Lewis VO, Roland CL, Bishop AJ. Hypofractionated, 3-week, preoperative radiotherapy for patients with soft tissue sarcomas (HYPORT-STS): a single-centre, open-label, single-arm, phase 2 trial. Lancet Oncol 23(12):1547-1557, 2022. e-Pub 2022. PMID: 36343656.
2. Thiebaud JA, Ravi V, Litwin S, Schuetze SM, Movva S, Agulnik M, Kraft AS, Tetzlaff ED, Somaiah N, von Mehren M. OER-073: A multicenter phase 2 study evaluating the role of pazopanib in angiosarcoma. Cancer 128(19):3516-3522, 2022. e-Pub 2022. PMID: 35942596.
3. Bishop AJ, Amini B, Lin H, Raza SM, Patel S, Grosshans DR, Ghia A, Farooqi A, Guadagnolo BA, Mitra D, Akdemir KC, Lazar AJ, Wang WL, Alvarez-Breckenridge C, Bird J, Rhines LD, Somaiah N, Conley AP. Immune Checkpoint Inhibitors Have Clinical Activity in Patients With Recurrent Chordoma. J Immunother 45(8):374-378, 2022. e-Pub 2022. PMID: 35943386.
4. Nathenson MJ, Hu J, Ratan R, Somaiah N, Hsu R, DeMaria PJ, Catoe HW, Pang A, Subhawong TK, Amini B, Sweet K, Feister K, Malik K, Jagannathan J, Braschi-Amirfarzan M, Sheren J, Caldas Y, Moreno Tellez C, Rosenberg AE, Lazar AJ, Maki RG, Benedetto P, Cohen J, Trent JC, Ravi V, Patel S, Wilky BA. Systemic chemotherapies retain anti-tumor activity in desmoid tumors independent of specific mutations in CTNNB1 or APC: A multi-institutional retrospective study. Clin Cancer Res 28(18):4092-4104, 2022. e-Pub 2022. PMID: 35180772.
5. Ravi V, Subramaniam A, Zheng J, Amini B, Trinh VA, Joseph J, Mennel RG, Bishop AJ, Sturgis EM, Goepfert RP, Yalamanchili S, Botello G, Stephen B, Piha-Paul SA, Patel AB, Lazar AJ, Conley AP, Benjamin RS, Patel SR, Futreal PA, Somaiah N, Naing A. Clinical activity of checkpoint inhibitors in angiosarcoma: A retrospective cohort study. Cancer 128(18):3383-3391, 2022. e-Pub 2022. PMID: 35792683.
6. Somaiah N, Conley AP, Parra ER, Lin H, Amini B, Solis Soto L, Salazar R, Barreto C, Chen H, Gite S, Haymaker C, Nassif EF, Bernatchez C, Mitra A, Livingston JA, Ravi V, Araujo DM, Benjamin R, Patel S, Zarzour MA, Sabir S, Lazar AJ, Wang WL, Daw NC, Zhou X, Roland CL, Cooper ZA, Rodriguez-Canales J, Futreal A, Soria JC, Wistuba II, Hwu P. Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial. Lancet Oncol 23(9):1156-1166, 2022. e-Pub 2022. PMID: 35934010.
7. Thirasastr P, Brahmi M, Dufresne A, Somaiah N, Blay JY. New Drug Approvals for Sarcoma in the Last 5 Years. Surg Oncol Clin N Am 31(3):361-380, 2022. PMID: 35715139.
8. Gounder MM, Agaram NP, Trabucco SE, Robinson V, Ferraro RA, Millis SZ, Krishnan A, Lee J, Attia S, Abida W, Drilon A, Chi P, Angelo SP, Dickson MA, Keohan ML, Kelly CM, Agulnik M, Chawla SP, Choy E, Chugh R, Meyer CF, Myer PA, Moore JL, Okimoto RA, Pollock RE, Ravi V, Singh AS, Somaiah N, Wagner AJ, Healey JH, Frampton GM, Venstrom JM, Ross JS, Ladanyi M, Singer S, Brennan MF, Schwartz GK, Lazar AJ, Thomas DM, Maki RG, Tap WD, Ali SM, Jin DX. Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma. Nat Commun 13(1):3406, 2022. e-Pub 2022. PMID: 35705558.
9. Boyce-Fappiano D, Damron EP, Farooqi A, Mitra D, Conley AP, Somaiah N, Araujo DM, Livingston JA, Ratan R, Keung EZ, Roland CL, Guadagnolo BA, Bishop AJ. Hypofractionated Radiation Therapy for Unresectable or Metastatic Sarcoma Lesions. Adv Radiat Oncol 7(3):100913, 2022. e-Pub 2022. PMID: 35647398.
10. Prapassorn Thirasastr, Neeta Somaiah. Overview of systemic therapy options in liposarcoma, with a focus on the activity of selinexor, a selective inhibitor of nuclear export in dedifferentiated liposarcoma. Therapeutic Advances in Medical Oncology, 2022.
11. Elise F. Nassif,Brandon Cope,Raymond Traweek,Russell G. Witt,Derek J. Erstad,Christopher P. Scally,Prapassorn Thirasastr,Maria Alejandra Zarzour,Joseph Ludwig,Robert Benjamin,Andrew J. Bishop,B. Ashleigh Guadagnolo,Davis Ingram,Khalida Wani,Wei-Lien Wang,Alexander J. Lazar,Keila E. Torres,Kelly K. Hunt,Barry W. Feig,Christina L. Roland,Neeta Somaiah,Emily Z. Keung. Real-world use of palbociclib monotherapy in retroperitoneal liposarcomas at a large volume sarcoma center. International Journal of Cancer, 2022.
12. Lazcano R, Barreto CM, Salazar R, Carapeto F, Traweek RS, Leung CH, Gite S, Mehta J, Ingram DR, Wani KM, Vu KT, Parra ER, Lu W, Zhou J, Witt RG, Cope B, Thirasastr P, Lin HY, Scally CP, Conley AP, Ratan R, Livingston JA, Zarzour AM, Ludwig J, Araujo D, Ravi V, Patel S, Benjamin R, Wargo J, Wistuba II, Somaiah N, Roland CL, Keung EZ, Solis L, Wang WL, Lazar AJ, Nassif EF. The immune landscape of undifferentiated pleomorphic sarcoma. Front Oncol 12:1008484, 2022. e-Pub 2022. PMID: 36313661.
13. Voss RK, Massarweh NN, Chiang YJ, Somaiah N, Feig BW, Roland CL. National Utilization of Imatinib in the Management of Resected Gastrointestinal Stromal Tumors. Ann Surg Oncol 28(13):9159-9168, 2021. e-Pub 2021. PMID: 34046772.
14. Voss RK, Massarweh NN, Chiang YJ, Somaiah N, Feig BW, Roland CL. ASO Visual Abstract: National Utilization of Imatinib in the Management of Resected Gastrointestinal Stromal Tumors. Ann Surg Oncol 28(Suppl 3):457, 2021. e-Pub 2021. PMID: 34050428.
15. Zalcberg JR, Heinrich MC, George S, Bauer S, Schöffski P, Serrano C, Gelderblom H, Jones RL, Attia S, D'Amato G, Chi P, Reichardt P, Somaiah N, Meade J, Reichert V, Shi K, Sherman ML, Ruiz-Soto R, von Mehren M, Blay JY. Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study. Oncologist 26(11):e2053-e2060, 2021. e-Pub 2021. PMID: 34313371.
16. George S, Chi P, Heinrich MC, von Mehren M, Jones RL, Ganjoo K, Trent J, Gelderblom H, Razak AA, Gordon MS, Somaiah N, Jennings J, Meade J, Shi K, Su Y, Ruiz-Soto R, Janku F. Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour. Eur J Cancer 155:236-244, 2021. e-Pub 2021. PMID: 34391056.
17. Gounder M, Abdul Razak AR, Gilligan AM, Leong H, Ma X, Somaiah N, Chawla SP, Martin-Broto J, Grignani G, Schuetze SM, Vincenzi B, Wagner AJ, Chmielowski B, Jones RL, Shah J, Shacham S, Kauffman M, Riedel RF, Attia S. Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma. Future Oncol 17(22):2923-2939, 2021. e-Pub 2021. PMID: 33855868.
18. Parkes A, Wang WL, Patel S, Leung CH, Lin H, Conley AP, Somaiah N, Araujo DM, Zarzour M, Livingston JA, Ludwig J, Roland CL, Ravi V, Benjamin RS, Ratan R. Outcomes of systemic therapy in metastatic phyllodes tumor of the breast. Breast Cancer Res Treat 186(3):871-882, 2021. e-Pub 2021. PMID: 33575859.
19. Somaiah N, Van Tine BA, Wahlquist AE, Milhem MM, Hill EG, Garrett-Mayer E, Armeson KE, Schuetze SM, Meyer CF, Reuben DY, Elias AD, Read WL, Chawla SP, Kraft AS. A randomized, open-label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft-tissue sarcoma. Cancer 127(6):894-904, 2021. e-Pub 2020. PMID: 33231866.
20. Bernd Kasper, Annie Achee, Kathrin Schuster, Roger Wilson, Gerard van Oortmerssen, Rebecca A. Gladdy, Matthew L. Hemming, Paul Huang, Matthew Ingham, Robin L. Jones, Seth M. Pollack, Denise Reinke, Roberta Sanfilippo, Scott M. Schuetze, Neeta Somaiah, Brian A. Van Tine, Breelyn Wilky, Scott Okuno, Jonathan Trent. Unmet Medical Needs and Future Perspectives for Leiomyosarcoma Patients—A Position Paper from the National Leiomyosarcoma Foundation (NLMSF) and Sarcoma Patients EuroNet (SPAEN). Cancers (MDPI) 13(4), 2021. e-Pub 2021.
21. Keung EZ, Rajkot N, Torres KE, Somaiah N, Hunt KK, Feig BW, Scally CP, Ikoma N, Roland CL. Evaluating the Impact of Surveillance Follow-Up Intervals in Patients Following Resection of Primary Well-Differentiated Liposarcoma of the Retroperitoneum. Ann Surg Oncol 28(1):570-575, 2021. e-Pub 2020. PMID: 32409969.
22. Somaiah N, Chawla SP, Block MS, Morris JC, Do K, Kim JW, Druta M, Sankhala KK, Hwu P, Jones RL, Gnjatic S, Kim-Schulze S, Tuballes K, Yishak M, Lu H, Yakovich A, Ter Meulen J, Chen M, Kenney RT, Bohac C, Pollack SM. A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1. Oncoimmunology 9(1):1847846, 2020. e-Pub 2020. PMID: 33312760.
23. Janku F, Abdul Razak AR, Chi P, Heinrich MC, von Mehren M, Jones RL, Ganjoo K, Trent J, Gelderblom H, Somaiah N, Hu S, Rosen O, Su Y, Ruiz-Soto R, Gordon M, George S. Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib. J Clin Oncol 38(28):3294-3303, 2020. e-Pub 2020. PMID: 32804590.
24. Pollack SM, Somaiah N, Araujo DM, Druta M, Van Tine BA, Burgess MA, Chawla SP, Seetharam M, Okuno SH, Bohac C, Chen M, Yurasov S, Attia S. Clinical outcomes of patients with advanced synovial sarcoma or myxoid/round cell liposarcoma treated at major cancer centers in the United States. Cancer Med 9(13):4593-4602, 2020. e-Pub 2020. PMID: 32374488.
25. Groisberg R, Roszik J, Conley AP, Lazar AJ, Portal DE, Hong DS, Naing A, Herzog CE, Somaiah N, Zarzour MA, Patel S, Brown RE, Subbiah V. Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental Therapies. Mol Cancer Ther 19(5):1165-1172, 2020. e-Pub 2020. PMID: 32127467.
26. Wu CC, Beird HC, Andrew Livingston J, Advani S, Mitra A, Cao S, Reuben A, Ingram D, Wang WL, Ju Z, Hong Leung C, Lin H, Zheng Y, Roszik J, Wang W, Patel S, Benjamin RS, Somaiah N, Conley AP, Mills GB, Hwu P, Gorlick R, Lazar A, Daw NC, Lewis V, Futreal PA. Immuno-genomic landscape of osteosarcoma. Nat Commun 11(1):1008, 2020. e-Pub 2020. PMID: 32081846.
27. Parkes A, Urquiola E, Bhosale P, Lin H, Watson K, Wang WL, Feig B, Torres K, Roland CL, Conley AP, Zarzour M, Livingston JA, Ratan R, Ludwig J, Araujo DM, Ravi V, Benjamin RS, Patel S, Somaiah N. PET/CT Imaging as a Diagnostic Tool in Distinguishing Well-Differentiated versus Dedifferentiated Liposarcoma. Sarcoma 2020:8363986, 2020. e-Pub 2020. PMID: 32565716.
28. Van Tine BA, Govindarajan R, Attia S, Somaiah N, Barker SS, Shahir A, Barrett E, Lee P, Wacheck V, Ramage SC, Tap WD. Incidence and Management of Olaratumab Infusion-Related Reactions. J Oncol Pract 15(11):e925-e933, 2019. e-Pub 2019. PMID: 31268811.
29. Somaiah N, Block MS, Kim JW, Shapiro GI, Do KT, Hwu P, Eder JP, Jones RL, Lu H, Ter Meulen JH, Bohac C, Chen M, Hsu FJ, Gnjatic S, Pollack SM. First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1. Clin Cancer Res 25(19):5808-5817, 2019. e-Pub 2019. PMID: 31227504.
30. Chrisinger JSA, Al-Zaid T, Keung EZ, Leung C, Lin HY, Roland CL, Torres KE, Benjamin RS, Ingram DR, Khan S, Somaiah N, Amini B, Feig BW, Lazar AJ, Wang WL. The degree of sclerosis is associated with prognosis in well-differentiated liposarcoma of the retroperitoneum. J Surg Oncol 120(3):382-388, 2019. e-Pub 2019. PMID: 31206726.
31. Subbiah V, Anderson PM, Kairemo K, Hess K, Huh WW, Ravi V, Daw NC, Somaiah N, Ludwig JA, Benjamin RS, Chawla S, Hong DS, Meric-Bernstam F, Ravizzini G, Kleinerman E, Macapinlac H, Rohren E. Alpha particle Radium 223 dichloride in high-risk osteosarcoma: a phase I dose escalation trial. Clin Cancer Res 25(13):3802-3810, 2019. e-Pub 2019. PMID: 30733229.
32. Conley AP, Wang WL, Livingston JA, Ravi V, Tsai JW, Ali A, Ingram DR, Lowery CD, Roland CL, Somaiah N, Hwu P, Yee C, Subbiah V, Futreal A, Lazar AJ, Patel S, Roszik J. MAGE-A3 is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma. Cancers (Basel) 11(5), 2019. e-Pub 2019. PMID: 31096717.
33. Keung Z, Somaiah N. Overview of liposarcomas and their genomic landscape. J Transl Genet Genom, 2019.
34. Wilkins A, Melcher A, Somaiah N. Science in Focus: Biological Optimisation of Radiotherapy Fraction Size in an Era of Immune Oncology. Clin Oncol (R Coll Radiol) 30(10):605-608, 2018. e-Pub 2018. PMID: 30041845.
35. Conley AP, Trinh VA, Zobniw CM, Posey K, Martinez JD, Arrieta OG, Wang WL, Lazar AJ, Somaiah N, Roszik J, Patel SR. Positive Tumor Response to Combined Checkpoint Inhibitors in a Patient With Refractory Alveolar Soft Part Sarcoma: A Case Report. J Glob Oncol DOI: 10.1200/JGO.2017.009993:1-6, 2018. e-Pub 2017. PMID: 30241159.
36. Dembla V, Somaiah N, Barata P, Hess K, Fu S, Janku F, Karp DD, Naing A, Piha-Paul SA, Subbiah V, Tsimberidou AM, Shaw K, Meric-Bernstam F, Hong DS. Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic. Oncotarget 9(69):33232-33243, 2018. e-Pub 2018. PMID: 30237864.
37. Keung EZ, Lazar AJ, Torres KE, Wang WL, Cormier JN, Ashleigh Guadagnolo B, Bishop AJ, Lin H, Hunt KK, Bird J, Lewis VO, Patel SR, Wargo JA, Somaiah N, Roland CL. Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. BMC Cancer 18(1):913, 2018. e-Pub 2018. PMID: 30249211.
38. Ikoma N, Roland CL, Torres KE, Chiang YJ, Wang WL, Somaiah N, Mann GN, Hunt KK, Cormier JN, Feig BW. Salvage Surgery for Recurrent Retroperitoneal Well-Differentiated Liposarcoma: Early Reoperation may not Provide Benefit. Ann Surg Oncol 25(8):2193-2200, 2018. e-Pub 2018. PMID: 29520652.
39. Ikoma N, Roland CL, Torres KE, Chiang YJ, Wang WL, Somaiah N, Mann GN, Hunt KK, Cormier JN, Feig BW. Concomitant organ resection does not improve outcomes in primary retroperitoneal well-differentiated liposarcoma: A retrospective cohort study at a major sarcoma center. J Surg Oncol 117(6):1188-1194, 2018. e-Pub 2017. PMID: 29228466.
40. Somaiah N, Beird HC, Barbo A, Song J, Mills Shaw KR, Wang WL, Eterovic K, Chen K, Lazar A, Conley AP, Ravi V, Hwu P, Futreal A, Simon G, Meric-Bernstam F, Hong D. Targeted next generation sequencing of well-differentiated/dedifferentiated liposarcoma reveals novel gene amplifications and mutations. Oncotarget 9(28):19891-19899, 2018. e-Pub 2018. PMID: 29731991.
41. Beird HC, Wu CC, Ingram DR, Wang WL, Alimohamed A, Gumbs C, Little L, Song X, Feig BW, Roland CL, Zhang J, Benjamin RS, Hwu P, Lazar AJ, Futreal PA, Somaiah N. Genomic profiling of dedifferentiated liposarcoma compared to matched well-differentiated liposarcoma reveals higher genomic complexity and a common origin. Cold Spring Harb Mol Case Stud 4(2), 2018. e-Pub 2018. PMID: 29610390.
42. Roland CL, Bednarski BK, Watson K, Torres KE, Cormier JN, Wang WL, Lazar AJ, Somaiah N, Hunt KK, Feig BW. Identification of preoperative factors associated with outcomes following surgical management of intra-abdominal recurrent or metastatic GIST following neoadjuvant tyrosine kinase inhibitor therapy. J Surg Oncol 117(5):879-885, 2018. e-Pub 2018. PMID: 29448300.
43. Zobniw CM, Trinh VA, Posey K, Somaiah N. Olaratumab in the management of advanced soft tissue sarcoma. J Oncol Pharm Pract((2)):442-448, 2018. PMID: 30032714.
44. Stacchiotti S, Mir O, Le Cesne A, Vincenzi B, Fedenko A, Maki RG, Somaiah N, Patel S, Brahmi M, Blay JY, Boye K, Sundby Hall K, Gelderblom H, Hindi N, Martin-Broto J, Kosela H, Rutkowski P, Italiano A, Duffaud F, Kobayashi E, Casali PG, Provenzano S, Kawai A. Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma. Oncologist 23(1):62-70, 2018. e-Pub 2017. PMID: 28754721.
45. Goumard C, Marcal LP, Wang WL, Somaiah N, Okuno M, Roland CL, Tzeng CD, Chun YS, Feig BW, Vauthey JN, Conrad C. Long-Term Survival According to Histology and Radiologic Response to Preoperative Chemotherapy in 126 Patients Undergoing Resection of Non-GIST Sarcoma Liver Metastases. Ann Surg Oncol 25(1):107-116, 2018. e-Pub 2017. PMID: 29116489.
46. Keung EZ, Tsai JW, Ali AM, Cormier JN, Bishop AJ, Guadagnolo BA, Torres KE, Somaiah N, Hunt KK, Wargo JA, Lazar AJ, Wang WL, Roland CL. Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy. Oncoimmunology 7(2):e1385689, 2018. e-Pub 2017. PMID: 29308306.
47. Li H, Meng QH, Noh H, Somaiah N, Torres KE, Xia X, Batth IS, Joseph CP, Liu M, Wang R, Li S. Cell-surface vimentin-positive macrophage-like circulating tumor cells as a novel biomarker of metastatic gastrointestinal stromal tumors. Oncoimmunology 7(5):e1420450, 2018. e-Pub 2018. PMID: 29721368.
48. Samuels BL, Chawla SP, Somaiah N, Staddon AP, Skubitz KM, Milhem MM, Kaiser PE, Portnoy DC, Priebat DA, Walker MS, Stepanski EJ. Results of a prospective phase 2 study of pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma. Cancer 123(23):4640-4647, 2017. e-Pub 2017. PMID: 28832986.
49. Groisberg R, Hong DS, Behrang A, Hess K, Janku F, Piha-Paul S, Naing A, Fu S, Benjamin R, Patel S, Somaiah N, Conley A, Meric-Bernstam F, Subbiah V. Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. J Immunother Cancer 5(1):100, 2017. e-Pub 2017. PMID: 29254498.
50. Dembla V, Groisberg R, Hess K, Fu S, Wheler J, Hong DS, Janku F, Zinner R, Piha-Paul SA, Ravi V, Benjamin RS, Patel S, Somaiah N, Herzog CE, Karp DD, Roszik J, Meric-Bernstam F, Subbiah V. Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors. Sci Rep 7(1):15963, 2017. e-Pub 2017. PMID: 29162825.
51. Reddy N, Moudgil R, Lopez-Mattei JC, Karimzad K, Mouhayar EN, Somaiah N, Conley AP, Patel S, Giza DE, Iliescu C. Progressive and Reversible Conduction Disease with Checkpoint Inhibitors. Can J Cardiol 33(10):1335.e13-1335.e15, 2017. e-Pub 2017. PMID: 28822650.
52. Pollack SM, Lu H, Gnjatic S, Somaiah N, O'Malley RB, Jones RL, Hsu FJ, Ter Meulen J. First-in-Human Treatment with a Dendritic Cell-Targeting Lentiviral Vector expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient. J Immunother 40(8):302-306, 2017. PMID: 28891906.
53. Wagner MJ, Gopalakrishnan V, Ravi V, Livingston JA, Conley AP, Araujo D, Somaiah N, Zarzour MA, Ratan R, Wang WL, Patel SR, Lazar A, Ludwig JA, Benjamin RS. Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults. Oncologist 22(10):1271-1277, 2017. e-Pub 2017. PMID: 28710342.
54. Francis AM, Alexander A, Liu Y, Vijayaraghavan S, Low KH, Yang D, Bui T, Somaiah N, Ravi V, Keyomarsi K, Hunt KK. CDK4/6 inhibitors sensitize Rb-positive sarcoma cells to Wee1 kinase inhibition through reversible cell cycle arrest. Mol Cancer Ther 16(9):1751-1764, 2017. e-Pub 2017. PMID: 28619757.
55. Li H, Meng QH, Noh H, Batth IS, Somaiah N, Torres KE, Xia X, Wang R, Li S. Detection of circulating tumor cells from cryopreserved human sarcoma peripheral blood mononuclear cells. Cancer Lett Jun 23;403:216-223. doi:10.1016/j.canlet.2017.05.032:216-223, 2017. e-Pub 2017. PMID: 28652021.
56. de Graaff MA, Malu S, Guardiola I, Kruisselbrink AB, de Jong Y, Corver WE, Gelderblom H, Hwu P, Nielsen TO, Lazar AJ, Somaiah N, Bovée JVMG. High-Throughput Screening of Myxoid Liposarcoma Cell Lines: Survivin Is Essential for Tumor Growth. Transl Oncol 10(4):546-554, 2017. e-Pub 2017. PMID: 28654818.
57. Jalal SI, Hanna N, Zon R, Masters GA, Borghaei H, Koneru K, Badve S, Prasad N, Somaiah N, Wu J, Yu Z, Einhorn L. Phase I Study of Amrubicin and Cyclophosphamide Patients with Advanced Solid Organ Malignancies: HOG LUN 07-130. Am J Clin Oncol 40(4):329-335, 2017. PMID: 25503432.
58. Schvartsman G, Wagner MJ, Amini B, Zobniw CM, Trinh VA, Barbo AG, Lin HY, Wang WL, Conley AP, Ravi V, Araujo DM, Zarzour MA, Benjamin RS, Patel S, Somaiah N. Treatment patterns, efficacy and toxicity of regorafenib in gastrointestinal stromal tumour patients. Sci Rep 7(1):9519, 2017. e-Pub 2017. PMID: 28842575.
59. Groisberg R, Hong DS, Holla V, Janku F, Piha-Paul S, Ravi V, Benjamin R, Kumar Patel S, Somaiah N, Conley A, Ali SM, Schrock AB, Ross JS, Stephens PJ, Miller VA, Sen S, Herzog C, Meric-Bernstam F, Subbiah V. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas. Oncotarget 8(24):39254-39267, 2017. PMID: 28424409.
60. Samuels BL, Chawla S, Somaiah N, Staddon A, Skubitz K, Milhem M, Kaiser P, Portnoy D, Priebat D, Walker MS, Stepanski EJ. Results of a Prospective Phase II Study of Pazopanib in Patients with Advanced Intermediate- or High-Grade Liposarcoma (CNCR-17-0785.R1). Cancer. Accepted, 2017.
61. Stacchiotti S, Mir O, Le Cesne A, Vincenzi B, Fedenko A, Maki RG, Somaiah N, Patel S, Brahmi M, Blay JY, Boye K, Sundby Hall K, Gelderblom H, Hindi N, Martin-Broto J, Kosela H, Rutkowski P, Italiano A, Duffaud F, Kobayashi E, Casali PG, Provenzano S, Kawai A. Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma (ASPS). The Oncologist, 2017.
62. Farag S, Somaiah N, Choi H, Heeres B, Wang WL, van Boven H, Nederlof P, Benjamin R, van der Graaf W, Grunhagen D, Boonstra PA, Reyners AK, Gelderblom H, Steeghs N. Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour patients. Eur J Cancer 76:76-83, 2017. e-Pub 2017. PMID: 28284172.
63. Wagner AJ, Banerji U, Mahipal A, Somaiah N, Hirsch H, Fancourt C, Johnson-Levonas AO, Lam R, Meister AK, Russo G, Knox CD, Rose S, Hong DS. Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors. J Clin Oncol 35(12):1304-1311, 2017. e-Pub 2017. PMID: 28240971.
64. Livingston JA, Bugano D, Barbo A, Lin H, Madewell JE, Wang WL, Lazar A, Tseng W, Roland CL, Feig B, Pollock R, Conley AP, Benjamin RS, Patel SR, Somaiah N. Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of the standard. Accepted with revisions. Scientific reports, 2017.
65. Quintana RA, Banchs J, Gupta R, Lin HY, Raj SD, Conley A, Ravi V, Araujo D, Benjamin RS, Patel S, Vadhan-Raj S, Somaiah N. Early evidence of cardiotoxicity and tumor response in patients with sarcomas after high cumulative dose doxorubicin given as a continuous infusion. Sarcoma 2017:7495914, 2017. e-Pub 2017. PMID: 29081684.
66. Bhosale P, Wang J, Varma D, Jensen C, Patnana M, Wei W, Chauhan A, Feig B, Patel S, Somaiah N, Sagebiel T. Can Abdominal Computed Tomography Imaging Help Accurately Identify a Dedifferentiated Component in a Well-Differentiated Liposarcoma?. J Comput Assist Tomogr 40(6):872-879(6):872-879, 2016. e-Pub 2016. PMID: 27454788.
67. Schvartsman G, Wagner MJ, Zobniw CM, Trinh VA, Patel S, Somaiah N. An Unusual Case of Central Retinal Vein Occlusion and Review of the Toxicity Profile of Regorafenib in GIST Patients. Curr Oncol Rep 18(8):49, 2016. PMID: 27319943.
68. de Graaff MA, Yu JS, Beird HC, Ingram DR, Nguyen T, Juehui Liu J, Bolshakov S, Szuhai K, Åman P, Torres KE, Lev D, Nielsen TO, Bovée JV, Lazar AJ, Somaiah N. Establishment and Characterization of a New Human Myxoid Liposarcoma Cell Line (DL-221) with the FUS-DDIT3 Translocation. Lab Invest Aug;96(8):885-94. doi: 10.1038/labinvest.2016.64(8):885-94, 2016. e-Pub 2016. PMID: 27270875.
69. Ikoma N, Torres KE, Somaiah N, Hunt KK, Cormier JN, Tseng W, Lev D, Pollock R, Wang WL, Feig B. Accuracy of Preoperative Percutaneous Biopsy for the Diagnosis of Retroperitoneal Liposarcoma Subtypes. Ann Surg Oncol 22(4):1068-72, 2015. e-Pub 2014. PMID: 25354575.
70. Endo M, de Graaff MA, Ingram DR, Lim S, Lev DC, Briaire-de Bruijn IH, Somaiah N, Bovée JV, Lazar AJ, Nielsen TO. NY-ESO-1 (CTAG1B) expression in mesenchymal tumors. Mod Pathol 28(4):587-95, 2015. e-Pub 2014. PMID: 25412843.
71. Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist RS, Hensing T, Horn L, Ramalingam SS, Rudin CM, Salgia R, Sequist LV, Shaw AT, Simon GR, Somaiah N, Spigel DR, Wrangle J, Johnson D, Herbst RS, Bunn P, Govindan R. Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol S1-63(1 Suppl 1):S1-63, 2015. PMID: 25535693.
72. Tseng WW, Malu S, Zhang M, Chen J, Sim GC, Wei W, Ingram D, Somaiah N, Lev DC, Pollock RE, Lizée G, Radvanyi L, Hwu P. Analysis of the intratumoral adaptive immune response in well differentiated and dedifferentiated retroperitoneal liposarcoma. Sarcoma 2015:547460, 2015. e-Pub 2015. PMID: 25705114.
73. Tseng WW, Somaiah N, Engleman EG. Potential for immunotherapy in soft tissue sarcoma. Hum Vaccun Immunother 10(11):3117-24, 2014. PMID: 25412843.
74. Tseng WW, Madewell JE, Wei W, Somaiah N, Lazar AJ, Ghadimi MP, Hoffman A, Pisters PW, Lev DC, Pollock RE. Locoregional Disease Patterns in Well-Differentiated and Dedifferentiated Retroperitoneal Liposarcoma: Implications for the Extent of Resection?. Ann Surg Oncol 21(7):2136-43, 2014. e-Pub 2014. PMID: 24705628.
75. Burgoyne AM, Somaiah N, Sicklick JK. Gastrointestinal stromal tumors in the setting of multiple tumor syndromes. Curr Opin Oncol 26(4):408-14, 2014. PMID: 24840526.
76. Satelli A, Mitra A, Cutrera JJ, Devarie M, Xia X, Ingram DR, Dibra D, Somaiah N, Torres KE, Ravi V, Ludwig JA, Kleinerman ES, Li S. Universal Marker and Detection Tool for Human Sarcoma Circulating Tumor Cells. Cancer Res 74(6):1645-50, 2014. e-Pub 2014. PMID: 24448245.
77. Al-Zaid T, Somaiah N, Lazar AJ. Targeted therapies for sarcomas: new roles for the pathologist. Histopathology 64(1):119-33, 2014. e-Pub 2013. PMID: 24117526.
78. Simon GR, Somaiah N. A tabulated summary of targeted and biologic therapies for non-small-cell lung cancer. Clin Lung Cancer 15(1):21-51, 2014. e-Pub 2013. PMID: 24377743.
79. Aggarwal C, Li L, Borghaei H, Mehra R, Somaiah N, Turaka A, Langer CJ, Simon GR. Multidisciplinary therapy of stage IIIA non-small-cell lung cancer: long-term outcome of chemoradiation with or without surgery. Cancer Control 21(1):57-62, 2014. PMID: 24357742.
80. Somaiah N, Fidler MJ, Garrett-Mayer E, Wahlquist A, Shirai K, Buckingham L, Hensing T, Bonomi P, Simon GR. Epidermal growth factor receptor (EGFR) mutations are exceptionally rare in thyroid transcription factor (TTF-1)-negative adenocarcinomas of the lung. Oncoscience 1(8):522-528, 2014. e-Pub 2014. PMID: 25594059.
81. Tseng WW, Somaiah N, Lazar AJ, Lev DC, Pollock RE. Novel systemic therapies in advanced liposarcoma: a review of recent clinical trial results. Cancers (Basel) 5(2):529-49, 2013. e-Pub 2013. PMID: 24216990.
82. Cauchi C, Somaiah N, Engstrom PF, Litwin S, Lopez M, Lee J, Davey M, Bove B, von Mehren M. Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib. Cancer Chemother Pharmacol 69(4):977-82, 2012. e-Pub 2011. PMID: 22119758.
83. Somaiah N, von Mehren M. New drugs and combinations for the treatment of soft tissue sarcoma: A review. Cancer Manag Res 2012:4:397-411, 2012. e-Pub 2012. PMID: 23226072.
84. Somaiah N, von Mehren M. New therapeutic approaches for advanced gastrointestinal stromal tumors. Hematol Oncol Clin North Am 23(1):139-50, x, 2009. PMID: 19248977.
85. Al-Zaid T, Wang WL, Somaiah N, Lazar AJ. Molecular profiling of sarcomas: new vistas for precision medicine. Virchows Arch doi:10.1007/s00428-017-2174-3. e-Pub 2017. PMID: 28664413.
86. Gounder MM, Razak AA, Somaiah N, Chawla S, Martin-Broto J, Grignani G, Schuetze SM, Vincenzi B, Wagner AJ, Chmielowski B, Jones RL, Riedel RF, Stacchiotti S, Loggers ET, Ganjoo KN, Le Cesne A, Italiano A, Garcia Del Muro X, Burgess M, Piperno-Neumann S, Ryan C, Mulcahy MF, Forscher C, Penel N, Okuno S, Elias A, Hartner L, Philip T, Alcindor T, Kasper B, Reichardt P, Lapeire L, Blay JY, Chevreau C, Valverde Morales CM, Schwartz GK, Chen JL, Deshpande H, Davis EJ, Nicholas G, Gröschel S, Hatcher H, Duffaud F, Herráez AC, Beveridge RD, Badalamenti G, Eriksson M, Meyer C, von Mehren M, Van Tine BA, Götze K, Mazzeo F, Yakobson A, Zick A, Lee A, Gonzalez AE, Napolitano A, Dickson MA, Michel D, Meng C, Li L, Liu J, Ben-Shahar O, Van Domelen DR, Walker CJ, Chang H, Landesman Y, Shah JJ, Shacham S, Kauffman MG, Attia S. Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. J Clin Oncol:JCO2101829. e-Pub 2022. PMID: 35394800.
87. Moyers JT, Carmagnani Pestana R, Roszik J, Hong DS, Naing A, Fu S, Piha-Paul S, Yap T, Karp D, Rodon J, Livingston JA, Zarzour MA, Ravi V, Patel S, Benjamin RS, Ludwig J, Herzog C, Ratan R, Somaiah N, Conley A, Gorlick R, Meric-Bernstam F, Subbiah V. Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102). Clin Cancer Res. e-Pub 2022. PMID: 36288393.
88. Thirasastr P, Lin H, Amini B, Wang WL, Cloutier JM, Nassif EF, Keung EZ, Roland CL, Feig B, Araujo D, Benjamin RS, Conley AP, Livingston JA, Ludwig J, Patel S, Ratan R, Ravi V, Zarzour MA, Zhou X, Somaiah N. Retrospective evaluation of the role of gemcitabine-docetaxel in well-differentiated and dedifferentiated liposarcoma. Cancer Med. e-Pub 2022. PMID: 36151848.

Invited Articles

1. Somaiah N. The Role of Combination Chemotherapy in GIST. GIST Cancer Journal, 2014.

Manuals, Teaching Aids, Other Teaching Publications

1. Elise Nassif, MD, Neeta Somaiah, MD. ASCO Daily News Article: Improving the Benchmark: Examining ASCO22 Histology-Specific Trials in Sarcoma, 2022.
2. Neeta Somaiah. ASCO Daily News Article: Rare Cancers-sarcoma commentary - Virtual Scientific Program. Rare Cancers-sarcoma commentary post-ASCO 2021 virtual Scientific Program, 2021.
3. Maria Alejandra Zarzour, MD, Neeta Somaiah, MD. ASCO Daily News Expert Panel. Highlights of New Sarcoma Research: ASCO 2020 Virtual Scientific Program, 2020.
4. Neeta Somaiah. ASCO 2020 Abstracts. Commentary on Sarcoma abstracts for Cardinal Health newsletter series on ASCO 2020 abstracts, 2020.
5. Somaiah N. VEGF - Targeting in Gastrointestinal Stromal Tumors, 2017.
6. Somaiah N. GIST Module. Clinical Care Options, 2015.

Other Articles

1. Symcox M, Somaiah N Ripretinib for advanced gastrointestinal stromal tumor: Plain language summary of the INVICTUS study. Future Oncol 17(36):5007-5012, 2021. PMID: 34661454.
2. Requested by Phyllis Pittman Sarcoma patient information. CmedED content review, 2021.

Abstracts

1. Raymond S. Traweek, MD, Neeta Somaiah, MD. Dietary fiber intake is associated with increased tertiary lymphoid structures in dedifferentiated liposarcoma following immune checkpoint blockade. SITC 37th Annual Meeting & Pre-Conference Programs(248666), 2022.
2. Ludwig,Joseph; Lee,Younghee; Rodriguez,Rebeca; Somaiah,Neeta; Livingston,John Andrew; Ingram,Davis R; Haymaker,Cara; Tomczak,Katarzyna J. The dual function of the adenosine pathway in Liposarcoma microenvironment. SITC 2022 Annual Meeting, 2022.
3. Jonathan Gill, Anthony P. Conley, Neeta Somaiah, Dejka M. Araujo, Ravin Ratan, Kristi Posey, Robert S. Benjamin, Shreyaskumar Patel, Najat C. Daw, Douglas J. Harrison, Richard Gorlick, Heather Lin, Wei-Lien Wang, Behrang Amini, Nancy Gordon, J. Andrew Livingston. A Phase 1/2 Trial of Gemcitabine, Docetaxel, and Hydroxychloroquine in Advanced / Metastatic Osteosarcoma: Results of Phase 1. CTOS 2022 Annual Meeting, 2022.
4. Heather G. Lyu, Heather A. Lillemoe, Yi-Ju Chiang, Emily Zhi-Yun Keung, Sa Thi Nguyen, Susan K. Peterson, Keila E Torres, Kelly Hunt, Barry W. Feig, Andrew Justin Bishop, Beverly Ashleigh Guadagnolo, Neeta Somaiah, Christina Lynn Roland, Christopher Scally. Health-related quality of life in patients with resectable undifferentiated pleomorphic sarcoma treated with neoadjuvant checkpoint blockade in a single institution randomized phase II clinical trial. ASCO 2022 Annual Meeting, 2022.
5. Neeta Somaiah, J Andrew Livingston, Vinod Ravi, Heather Y. Lin, Behrang Amini, Luisa Maren Solis, Anthony Paul Conley, Maria Alejandra Zarzour, Joseph Aloysius Ludwig, Ravin Ratan, Wei-Lien Wang, Dejka M. Araujo, Shreyaskumar Patel, Christina Lynn Roland, Alexander J. Lazar, Richard Greg Gorlick, Edwin R. Parra, Cara L. Haymake. A phase II multi-arm study to test the efficacy of oleclumab and durvalumab in specific sarcoma subtypes. ASCO 2022 Annual Meeting, 2022.
6. : Suzanne George, Michael C. Heinrich, Neeta Somaiah, Brian Andrew Van Tine, Robert McLeod, Abderrahmane Laadem, Ben Cheng, Satoshi Nishioka, Madan Gopal Kundu, Xiaozhong Qian, Yvonne Y. Lau, Brittany Tran, Prasanna Kumar, Ololade Dosunmu, Julia Shi, Yoichi Naito. A phase 1, multicenter, open-label, first-in-human study of DS-6157a in patients (pts) with advanced gastrointestinal stromal tumor (GIST). ASCO 2022 Annual Meeting, 2022.
7. Michael Nakazawa, J Andrew Livingston, Andrew Justin Bishop, Maria Alejandra Zarzour, Neeta Somaiah, Ravin Ratan, Jonathan Benjamin Gill, Elizabeth Urquiola, Kristi Posey, Beverly Ashleigh Guadagnolo, Richard Greg Gorlick, Robert S. Benjamin, Shreyaskumar Patel, Anthony Paul Conley. Clinical characteristics and outcomes of adult alveolar rhabdomyosarcoma (ARMS) patients on front-line therapies: An MD Anderson Cancer Center (MDACC) case series. ASCO 2022 Annual Meeting, 2022.
8. Elise F Nassif, Manoj Chelvanambi, Lili Chen, Chia-Chin Wu, Ashish Damania, Emily Zhi-Yun Keung, Russell G. Witt, Michael White, Nadim J. Ajami, Matthew C. Wong, Neeta Somaiah, Boris Sepesi, Sreyashi Basu, James Patrick Allison, Padmanee Sharma, Kevin McBride, Wolf-Hervé Fridman, Jennifer Ann Wargo, Tina Cascone, Christina Lynn Roland. Identifying gut microbial signatures associated with B cells and tertiary lymphoid structures (TLS) in the tumor microenvironment (TME) in response to immune checkpoint blockade (ICB). ASCO 2022 Annual Meeting, 2022.
9. Meredith McKean, Anthony W. Tolcher, James Andrew Reeves, Bartosz Chmielowski, Montaser F. Shaheen, Joseph Thaddeus Beck, Marlana M. Orloff, Neeta Somaiah, Brian Andrew Van Tine, Joseph J. Drabick, Alexander I. Spira, Kenneth O'byrne, Christos S. Karapetis, Steven A. Foresto, Sujana Movva, Jose Martinez, Mingyu Li, Robert Winkler, Dajun Yang, Yifan Zhai. Newly updated activity results of alrizomadlin (APG-115), a novel MDM2/p53 inhibitor, plus pembrolizumab: Phase 2 study in adults and children with various solid tumors. ASCO 2022 Annual Meeting, 2022.
10. Prapassorn Thirasastr, Cissimol Joseph, Dejka M. Araujo, Robert S. Benjamin, Anthony Paul Conley, J Andrew Andrew Livingston, Joseph Aloysius Ludwig, Shreyaskumar Patel, Ravin Ratan, Vinod Ravi, Maria Alejandra Zarzour, Xiao Zhou, Neeta Somaiah. Outcomes in late-line systemic treatment in GISTs: Does sequence matter?. ASCO 2022 Annual Meeting, 2022.
11. Blessie Elizabeth Nelson, Sadia Saleem, Senthil Damodaran, Neeta Somaiah, Sarina Anne Piha-Paul, Julia Ann Moore, Bulent Yilmaz, Daniel D. Karp, Ecaterina Elena Dumbrava, Apostolia Maria Tsimberidou, David S. Hong, Jordi Rodon Ahnert, Daniel J. Booser, Nuhad K. Ibrahim, Anthony Paul Conley, Priya Bhosale, Cristhiam Mauricio Rojas Hernandez, Debu Tripathy, Aung Naing, Funda Meric-Bernstam; University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Southwestern Medical Center, Dallas, TX; The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX; University of Texas MD Anderson Cancer Center, Department of Sarcoma Medical Oncology, Houston, TX; MD Anderson Cancer Center, Houston, TX. Phase Ib study of selinexor and eribulin combination in advanced solid tumors and triple negative breast cancer. ASCO 2022 Annual Meeting, 2022.
12. Sandra P. D'Angelo, Mihaela Druta, Brian Andrew Van Tine, David A. Liebner, Scott Schuetze, Michael Nathenson, Andrew P. Holmes, Jimson D'Souza, Gurpreet Singh Kapoor, Stefan Zajic, Neeta Somaiah Center. Primary efficacy and safety of letetresgene autoleucel (lete-cel; GSK3377794) pilot study in patients with advanced and metastatic myxoid/round cell liposarcoma (MRCLS). ASCO 2022 Annual Meeting, 2022.
13. Emily Zhi-Yun Keung, Elise F Nassif, Heather Y. Lin, Alexander J. Lazar, Keila E Torres, Wei-Lien Wang, Beverly Ashleigh Guadagnolo, Andrew Justin Bishop, Kelly Hunt, Barry W. Feig, Justin E. Bird, Valerae O. Lewis, Ravin Ratan, Shreyaskumar Patel, Monika Zelazowska, Bin Liu, Kevin McBride, Jennifer Ann Wargo, Christina Lynn Roland, Neeta Somaiah. Randomized phase II study of neoadjuvant checkpoint blockade for surgically resectable undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS): Survival results after 2 years of follow-up and intratumoral B-Cell Receptor (BCR) correlates. ASCO 2022 Annual Meeting, 2022.
14. Tuyen Duong Thanh Nguyen, Marc A. Pina, Yang Wang, Cansu Karakas, Tuyen N. Bui, Osama Mawlawi, Alexander J. Lazar, Davis R. Ingram, Rossana N. Lazcano Segura, Peter J. Hougton, Neeta Somaiah, Kelly K. Hunt, Khandan Keyomarsi. Early proliferative response via 18FLT-PET/CT and serum TK1 activity are predictive biomarkers for synergistic effect of sequential cell cycle targeted therapy in sarcoma. AACR 2022 Annual Meeting, 2022.
15. Gurpreet Kapoor1, Stefan Zajic1, Sunil Suchindran1, Jaegil Kim1, Ioanna Eleftheriadou1, Anne Huff1, Michael Nathenson1, Mihaela Druta2, Brian Van Tine3, Neeta Somaiah4, David Liebner5, Scott Schuetze6 and Sandra D’Angelo7.  Biomarker correlates of response in patients with advanced myxoid/round cell liposarcoma (MRCLS) treated with NY-ESO-1 TCR T cells (Letetresgene autoleucel). SITC 36th Anniversary Annual Meeting (SITC 2021) Abstracts 9(Suppl 2), 2021.
16. Emily Keung, Elise Nassif, Heather Lin, Alexander Lazar, Wei-Lien Wang, Edwin Parra, Cibelle Lima, Ignacio Wistuba, Ashleigh Guadagnolo, Andrew Bishop, Valerae Lewis, Keila Torres, Kelly Hunt, Barry Feig, Christopher Scally, Ahmed Al Rawi, Shadarra Crosby, Grace Mathew, Davis Ingram, Khalida Wani, Jennifer Wargo, Neeta Somaiah, Christina Roland. Immune infiltrates are associated with clinical outcomes in patients with resectable soft tissue sarcoma (STS) treated with neoadjuvant immune checkpoint blockade (ICB). SITC 36th Annual Meeting & Pre-Conference Programs, 2021.
17. Sandra P. D'Angelo, Mihaela Druta, Brian Andrew Van Tine, David A. Liebner, Scott Schuetze, Aisha N. Hasan, Andrew P. Holmes, Anne Huff, Gurpreet Singh Kapoor, Stefan Zajic, Neeta Somaiah. Safety and efficacy of letetresgene autoleucel (lete-cel; GSK3377794) in advanced myxoid/round cell liposarcoma (MRCLS) following high lymphodepletion (Cohort 2): interim analysis. CTOS 2021 Virtual Meeting, 2021.
18. 103. Prapassorn Thirasastr, Behrang Amini, Heather Lin, Christina Roland, Barry Feig, Emily Keung, Elise Nassif, Dejka Araujo, Robert S. Benjamin, Anthony P. Conley, John A. Livingston, Joseph Ludwig, Shreyaskumar Patel, Ravin Ratan, Vinod Ravi, Alex Zarzour, Xiao Zhou, Neeta Somaiah. Efficacy of Gemcitabine- Docetaxel in Dedifferentiated Liposarcoma. Poster Discussion. CTOS 2021 Virtual Meeting, 2021.
19. Brian Andrew Van Tine, Sant P. Chawla, Jonathan C. Trent, Breelyn A. Wilky, Rashmi Chugh, Bartosz Chmielowski, Shivaani Kummar, Atrayee Basu Mallick, Neeta Somaiah, Lee D. Cranmer, Mark Agulnik, Vicki Leigh Keedy, Silvia Stacchiotti, Bruno Vincenzi, Giuseppe Badalamenti, Brittany L Siontis, Steven Attia. A phase III study (APROMISS) of AL3818 (Catequentinib, Anlotinib) hydrochloride monotherapy in subjects with metastatic or advanced synovial sarcoma. ASCO 2021 Virtual Annual Meeting, 2021.
20. John Raymond Zalcberg, Michael C. Heinrich, Suzanne George, Sebastian Bauer, Patrick Schoffski, Cesar Serrano, Robin Lewis Jones, Hans Gelderblom, Steven Attia, Gina Z. D'Amato, Ping Chi, Peter Reichardt, Neeta Somaiah, Julie Nicole Meade, VIENNA Lynn REICHERT, Kelvin Shi, Matthew L. Sherman, Rodrigo Ruiz-Soto, Margaret von Mehren, Jean-Yves Blay. Intra-patient dose escalation (IPDE) of ripretinib after disease progression in patients with advanced gastrointestinal stromal tumor (GIST): Analyses from the phase 3 INVICTUS study. ASCO 2021 Virtual Annual Meeting (Deciphera Pharmaceuticals LLC), 2021.
21. Anthony W. Tolcher, James Andrew Reeves, Meredith McKean, Bartosz Chmielowski, Joseph Thaddeus Beck, Montaser F. Shaheen, Neeta Somaiah, Melissa Wilson, Alexander I. Spira, Joseph J. Drabick, Yuefen Tang, Robert Winkler, Mingyu Li, Mohammad Ahmad, Ming Lu, Zhiyan Liang, Dajun Yang, Yifan Zhai. Preliminary results of a phase II study of alrizomadlin (APG-115), a novel, small-molecule MDM2 inhibitor, in combination with pembrolizumab in patients (pts) with unresectable or metastatic melanoma or advanced solid tumors that have failed immuno-oncologic (I-O) drugs. ASCO 2021 Virtual Annual Meeting (Ascentage Pharma Group LTD, Hong Kong), 2021.
22. Suzanne George, Filip Janku, Ping Chi, Margaret von Mehren, Neeta Somaiah, Hans Gelderblom, Robin L. Jones, Martine Allard, Adekemi Taylor, Xiaoyan Li, Julie Meade, Vienna Reichert, Rodrigo Ruiz-Soto, Jing Wang, Michael Heinrich. Population pharmacokinetics of ripretinib in patients with advanced malignancies. AACR 2021 Virtual Annual Meeting, 2021.
23. Meric-Bernstam, Funda; Somaiah, Neeta; Janku,Filip; Piha-Paul,Sarina Anne; Rodon Ahnert,Jordi; Pant,Shubham. Whole exome sequencing of tumor tissue and circulating tumor DNA ingastrointestinal stromal tumors (GIST). AACR Virtual Annual Meeting 2021(Abstract Control Number: 5360), 2021.
24. Suzanne George, Ping Chi, Michael Heinrich, Margaret vonMehren, Robin L. Jones, Kristen Ganjoo, Jonathan Trent, Hans Gelderblom, Albiruni Abdul Razak, Michael Gordon, Neeta Somaiah, Julia Jennings, Kelvin Shi, Rodrigo Ruiz-Soto, Filip Janku. Ripretinib intra-patient dose escalation following disease progression provides meaningful PFS in GIST phase 1 study. CTOS. CTOS 2020 Virtual Meeting, 2020.
25. Michael Nathenson, Neeta Somaiah, Robert Hsu, Peter J. DeMaria, Heath Catoe, Ty Subhawong, Behrang Amini, Kevin Sweet, Angela Pang, Junxiao Hu, Jamie Sheren, Andrew Rosenberg, Alexander Lazar, Ravin Ratan, Vinod Ravi, Shreyaskumar Patel, Robert Maki, Pasquale Benedetto, Jonathan Cohen, Jonathan Trent, Breelyn Wilky. Association of CTNNB1 mutation subtypes with responses to systemic therapy in patients with desmoid tumors: A multi-institutional retrospective study. CTOS 2020 Virtual Meeting, 2020.
26. Mrinal Gounder, Albiruni Razak, Neeta Somaiah, Javier Martin-Broto, Scott Schuetze, Giovanni Grignani, Sant Chawla, Bartosz Chmielowski, Bruno Vincenzi, Silvia Stacchiotti, Andrew J. Wagner, Axel Le Cesne, Richard F. Riedel, Robin L. Jones, Kristen N. Ganjoo, Xavier Garcia del Muro, Melissa Amber Burgess, Dayana Michel, Hongwei Wang, Jatin J. Shah, Steven Attia. A Phase 2/3, Randomized, Double Blind, Cross-Over, Study of Selinexor versus Placebo in Advanced Unresectable DeDifferentiated Liposarcoma (DDLS). CTOS 2020 Virtual Meeting, 2020.
27. Emily Z. Keung, Elise F. Nassif, Heather Lin, Alexander J. Lazar, Wei-Lien Wang, Edwin Parra Cuentas, Ignacio Wistuba, B. Ashleigh Guadagnolo, Andrew J. Bishop, Valerae Lewis, Keila E. Torres, Kelly K. Hunt, Barry W. Feig, Chris P. Scally, Ahmed N. Al Rawi, Shadarra Crosby, Grace Mathew, Davis Ingram, Khalida Wani, Jennifer A. Wargo, Neeta Somaiah, Christina L. Roland.. Sarcoma immune infiltrates are associated with clinical outcomes in patients with resectable soft tissue sarcoma treated with neoadjuvant immune checkpoint blockade (ICB). SITC 2020 Annual Meeting, 2020.
28. Roland C, Keung E, Lazar A, Torres K, Wei-Lien W, Guadagnolo A, Bishop A, Lin H, Hunt K, Feig B, Bird J, Lewis V, Tawbi H, Ratan R, Patel S, Wargo J, Somaiah N. Preliminary results of a phase II study of neoadjuvant checkpoint blockade for surgically resectable undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS). J Clin Oncol, ASCO Virtual Scientific Program 2020(38), 2020.
29. Neeta Somaiah, Anthony Paul Conley, Heather Y. Lin, Behrang Amini, Sharjeel H Sabir, Dejka M. Araujo, Robert S. Benjamin, J Andrew Livingston, Shreyaskumar Patel, Ravin Ratan, Vinod Ravi, Maria Alejandra Zarzour, Wei-Lien Wang, Taylor Tate, Christina Lynn Roland, Najat C. Daw, Andrew Futreal, Alexander J. Lazar, Ignacio Ivan Wistuba, Patrick Hwu. A phase II multi-arm study to test the efficacy of oleclumab and durvalumab in specific sarcoma subtypes. 2020 ASCO Virtual Scientific Program, 2020.
30. Somaiah N, Van Tine BA, Goodwin-Hill E, Milhem M. Phase II trial of gemcitabine (G) with pazopanib (P) or gemcitabine with docetaxel (T) in advanced soft tissue sarcoma (STS). J Clin Oncol, ASCO Annual Meeting 2019(37), 2019.
31. von Mehren M, Litwin S, Vinod R, Schuetze S, Movva S, Agulnik M, Kraft A, Tetzlaff E, Somaiah N. Multicenter phase II trial of pazopanib (P) in patients with angiosarcoma (AS). J Clin Oncol, ASCO Annual Meeting 2019(37), 2019. e-Pub 2019.
32. Attia S, Pollack S, Van Tine BA, Chawla S, Druta M, Burgess M, Bohac G, Somaiah N. Clinical outcomes from a retrospective registry of patients with locally advanced/metastatic synovial sarcoma and myxoid round cell liposarcoma. J Clin Oncol, ASCO Annual Meeting 2019(37), 2019.
33. D'Angelo S, Druta M, Liebner D, Schuetze S, Somaiah N, Van Tine B, Tap W, Pulham T, Chagin K, Norry E, Amado R. Pilot study of NY-ESO-1c259T cells in advanced myxoid/round cell liposarcoma. ASCO 2018 Annual Meeting, 2018.
34. Neeta Somaiah, Sant P. Chawla, Matthew Stephen Block, John Charles Morris, Khanh Tu Do, Joseph W. Kim, Mihaela Druta, Kamalesh Kumar Sankhala, Patrick Hwu, Sacha Gnjatic, Hailing Lu, Richard T. Kenney, Gerry C. Bohac, Seth Pollack. Immune response, safety, and survival impact from CMB305 in NY-ESO-1+ recurrent soft tissue sarcomas (STS). J Clin Oncol, ASCO Annual Meeting 2017, 2017.
35. Seth Pollack, Hailing Lu, Neeta Somaiah, Sant P. Chawla, John Charles Morris, Khanh Tu Do, Joseph W. Kim, Matthew Stephen Block, Marissa Vignali, Julie Rytlewski, Erik Yusko, Frank J. Hsu, Gerry C. Bohac, Sacha Gnjatic. Association of CMB305 or LV305-induced and baseline anti-NY-ESO-1 immunity with survival in recurrent cancer patients. J Clin Oncol 35, 2017.
36. Sandra P. D'Angelo, Mihaela Druta, George D. Demetri, David A. Liebner, Scott Schuetze, Arun S. Singh, Neeta Somaiah, Brian Andrew Van Tine, Breelyn A. Wilky, Karen Chagin, Tim Pulham, Malini Iyengar, Elliot Norry, Arundathy N. Bartlett-Pandite, Rafael G. Amado. A pilot study of NY-ESO-1c259 T cells in subjects with advanced myxoid/round cell liposarcoma (NCT02992743). J Clin Oncol 35, 2017.
37. John Andrew Livingston, Kristi Posey, Vivek Subbiah, Najat C. Daw, Neeta Somaiah, Vinod Ravi, Shreyaskumar Patel, Robert S. Benjamin, Wei-Lien Wang, Alexander Lazar, Russell Broaddus, Funda Meric-Bernstam, Kenna Rael Shaw, Jason Roszik, Anthony Paul Conley. Analysis of osteosarcoma subtypes by clinical genomic testing to identify clinically actionable alterations. J Clin Oncol 35, 2017.
38. Filip Janku, Albiruni Ryan Abdul Razak, Michael S. Gordon, David Glenn Brooks, Daniel Lee Flynn, Michael Kaufman, Jama Pitman, Bryan Douglas Smith, Neeta Somaiah, John Frederick De Groot, Guo Chen, Julia Jennings, Samer Salah, Deb Westwood, Eric Gerstenberger, Oliver Rosen, Suzanne George. Pharmacokinetic-driven phase I study of DCC-2618 a pan-KIT and PDGFR inhibitor in patients (pts) with gastrointestinal stromal tumor (GIST) and other solid tumors. J Clin Oncol 35, 2017.
39. Schvartsman G, Wagner M, Barbo A, Lin H, Amini B, Trinh V, Wang WL, Patel SR, Benjamin RS, Somaiah N, The University of Texas MD Anderson Cancer Center. The Toxicity & Efficacy Profile of Regorafenib (RG) in Gastrointestinal Tumor (GIST) Patients Using An Alternate Dosing Regimen. Connective Tissue Oncology Society 2016, 2016.
40. Subbiah V, Anerson P, Kairemo K, Huh W, Ravi V, Daw N, Somaiah N, Benjamin B, Hong D, Macapinlac H, Ravizzini G, Rohren E. Alpha particle radium-223 dichloride (223RaCI2) therapy and personalized molecular imaging with bone scintigraphy, NAF-PET and FDG-PET in high risk osteosarcoma. Connective Tissue Oncology Society 2016, 2016.
41. Yu J, Wu C, Beird H, Bovee J, Lazar A, Somaiah N, Nielsen T. Myxoid Liposarcoma Fusion Protein FUS-DDIT3 Associates with PARP1, RNA Processing & DBHS Family Proteins (SFPS, NONO, PSPC1). Connective Tissue Oncology Society 2016, 2016.
42. Conley A, Wang WL, Ravi V, Roland C, Somaiah N, Hwu P, Yee C, Futreal A, Lazar A, Rosnik J. MAGEA3 Expression & Clinical Correlation In Sarcoma Subtypes. Connective Tissue Oncology Society 2016, 2016.
43. Conley A, Ravi V, Somaiah N, Patel SR, Benjamin RS, Zarzour MA, Ludwig JA, Araujo D, Huh W, Subbiah V. Safety, Toxicity, & Activity of Multi-Kinase VEGFR TKI Vandetanib Combined with MTOR Inhibitor Everolmus in an Advanced Sarcomas Cohort of a Phase I Study. Connective Tissue Oncology Society 2016, 2016.
44. Nathenson M, Ravi V, Lin H, Wang WL, Lazar A, Araujo D, Somaiah N, Zarzour MA, Ratan R, Patel SR, Benjamin RS, Conley A. The Role of Estrogen and Progesterone as Prognostic Factors for Adenosarcoma of the Uterus. Connective Tissue Oncology Society 2016, 2016.
45. Stacchiotti S, Mir O, Vincenzi B, Fedenko A, Maki RG, Somaiah N, Brhami M, Boye K, Hindi N, Paterczyk HK, Italiano A, Kobayashi E, Provenzo S, Kawai A. Pazopanib (P) and Trabectedin (T) in alveolar soft part sarcoma (ASPS). Connective Tissue Oncology Society 2016, 2016.
46. Nathenson MJ, Conley AP, Lin HY, Wang WL, Lazar A, Araujo D, Somaiah N, Zarzour MA, Ratan R, Patel SR, Benjamin RS, Ravi V. Prognostic Factors for Adenosarcoma of the Uterus. Connective Tissue Oncology Society 2016, 2016.
47. Neeta Somaiah, Matthew Stephen Block, Joseph W. Kim, Geoffrey Shapiro, Khanh Tu Do, Patrick Hwu, Joseph Paul Eder, Robin Lewis Jones, Sacha Gnjatic, Hailing Lu, Jan Ter Meulen, Frank J. Hsu, Seth Pollack; The University of Texas MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; Yale University-Yale Cancer Center, New Haven, CT; Dana-Farber Cancer Institute, Boston, MA; Fred Hutchinson Cancer Research Center, Seattle, WA; Icahn School of Medicine at Mount Sinai, New York, NY; Immune Design, Seattle, WA. Single-agent LV305 to induce anti-tumor immune & clinical responses in patients with advanced or metastatic sarcoma. J Clin Oncol, ASCO Annual Meeting 2016(34), 2016. e-Pub 2016.
48. Michael Nathenson, Anthony Paul Conley, Ravin Ratan, Maria Alejandra Zarzour, Neeta Somaiah, Dejka M. Araujo, Shreyaskumar Patel, Robert S. Benjamin, Vinod Ravi. Efficacy of front-line chemotherapy for recurrent/metastatic Adenosarcoma of the uterus. J Clin Oncol, ASCO Annual Meeting 2016(34), 2016.
49. Vivek Subbiah, Peter Meade Anderson, Kalevi Kairemo, Winston W. Huh, Vinod Ravi, Najat C. Daw, Neeta Somaiah, Robert S. Benjamin, David S. Hong, Gregory Ravizzini, Eric Rohren. Alpha particle radium-223 dichloride (223RaCI2) in high risk osteosarcoma. J Clin Oncol, ASCO Annual Meeting 2016(34), 2016.
50. Anthony Paul Conley, Winston W. Huh, Jason Roszik, Douglas James Harrison, Andrea Anita Hayes-Jordan, Kathleen A Kehr, Ravin Ratan, Neeta Somaiah, Vinod Ravi, Dejka M. Araujo, Maria Alejandra Zarzour, Joseph A. Ludwig, Wei-Lien Wang, Robert S. Benjamin, Shreyaskumar Patel. Clinical characteristics of adult alveolar rhabdomyosarcoma (ARMS) patients (Pts) on front-line therapies. J Clin Oncol, ASCO Annual Meeting 2016(34), 2016.
51. Roman Groisberg, David S. Hong, Filip Janku, Sarina Anne Piha-Paul, Vinod Ravi, Robert S. Benjamin, Shreyaskumar Patel, Neeta Somaiah, Anthony Paul Conley, Cynthia E. Herzog, Funda Meric-Bernstam, Vivek Subbiah. Clinical next-generation sequencing in sarcomas. J Clin Oncol, ASCO Annual Meeting 2016(34), 2016.
52. Mrinal M. Gounder, Andrew J. Wagner, Neeta Somaiah, Richard F. Riedel, Gary K. Schwartz, Steven Attia, Albiruni R.A. Razak, Lee D. Cranmer, Scott H. Okuno, Mohammed M. Milhem, Cassandra Choe-Juliak, Sharon Shacham, Michael G. Kauffman, Sant P. Chawla; Memorial Sloan Kettering Cancer Center, New York, NY; Dana-Farber Cancer Institute, Boston, MA; The University of Texas MD Anderson Cancer Center, Houston, TX; Duke University Medical Center, Durham, NC; Columbia University Medical Center - New York Presbyterian Hospital, New York, NY; Mayo Clinic, Jacksonville, FL; Princess Margaret Hospital, Toronto, ON, Canada; University of Arizona Cancer Center, Tucson, AZ; Mayo Clinic, Rochester, MN; University of Iowa Hospitals and Clinics, Holden Comprehensive Cancer Center, Iowa City, IA; Karyopharm Therapeutics, Inc, Newton, MA; Director, Sarcoma Oncology Center, Santa Monica, CA. The Selinexor in Advanced Liposarcoma (SEAL) study: A phase 2/3, mulit-center, randomized blind study. J Clin Oncol, ASCO Annual Meeting 2016(34), 2016.
53. Sheima Farag, Neeta Somaiah, Haesun Choi, Birthe Heeres, Wei-Lien Wang, Hester Van Boven, Petra M Nederlof, Robert S. Benjamin, Winette TA van der Graaf, Dirk J. Grunhagen, Pieter Boonstra, An K.L Reyners, Hans Gelderblom, Neeltje Steeghs. Clinical characteristics & treatment outcome in a large multicenter observational cohort of pdgfraexon 18 mutated. J Clin Oncol, ASCO Annual Meeting 2016(34), 2016.
54. Vikas Dembla, Siqing Fu, Jennifer Wheler, David S. Hong, Filip Janku, Ralph Zinner, Sarina Anne Piha-Paul, Vinod Ravi, Robert S. Benjamin, Shreyaskumar Patel, Neeta Somaiah, Cynthia E. Herzog, Daniel D. Karp, Funda Meric-Bernstam, Vivek Subbiah. Outcomes of patients with advance sarcoma enrolled in clinical trials of pazopanib in combination of histone deacetylase. J Clin Oncol, ASCO Annual Meeting 2016(34), 2016.
55. Mrinal M. Gounder, Todd Michael Bauer, Gary K. Schwartz, Tyler Masters, Richard D. Carvajal, Saeheum Song, Prasanna Kumar, Roohi Gajee, Oleg Zernovak, Michael M. Rosen, Jarema Peter Kochan, Shuquan Chen, David Michael Hyman, Sugun Gokmen, Funda Meric-Bernstam, Patricia LoRusso, Neeta Somaiah, Amy M. Weise, David S. Hong. A phase 1 study of the MDM2 inhibitor DS-3032b in patients (pts) with advanced solid tumors & lymphoma. J Clin Oncol, ASCO Annual Meeting 2016(34), 2016.
56. Anthony Paul Conley, Winston W. Huh, Jason Roszik, Douglas James Harrison, Andrea Anita Hayes-Jordan, Kathleen A Kehr, Ravin Ratan, Neeta Somaiah, Vinod Ravi, Dejka M. Araujo, Maria Alejandra Zarzour, Joseph A. Ludwig, Wei-Lien Wang, Robert S. Benjamin, Shreyaskumar Patel. Clinical characteristics of adult alveolar rhabdomyosarcoma (ARMS) patients (Pts) on front-line therapies: An MD Anderson Cancer Center (MDACC) series. ASCO Annual Meeting, 2016.
57. Marieke A. de Graaff, MD, Shruti Malu, Alwine Kruisselbrink, Irma Guardiola, Patrick Hwu, Torsten O. Nielsen, Alexander J. Lazar, Neeta Somaiah, Judith Bovee. Identification of Novel Drugable Targets for the Treatment of Myxoid Liposarcomas. Connective Tissue Oncology Society (CTOS) Annual Meeting 2015, 2015.
58. Daniela Katz, Heather Lin, Nikki Weaver, Johnathan Trent, Ariel Hammerman, PhD, Ilan Feldhamer, Dejka Araujo, Vinod Ravi, Anthony Conley, Wei-Lien Wang, Alexander Lazar, Shreyaskumar Patel, Robert Benjamin, Neeta Somaiah. Predicting Response to Second-Line Sunitinib (SU) Based on Duration of Treatment on Front-Line Imatinib (IM) Patients with Metastatic GIST. Connective Tissue Oncology Society (CTOS) Annual Meeting 2015, 2015.
59. Vivek Subbiah, MD, Pete Anderson, Winston W. Huh, Vinod Ravi, Kenneth Hess, Najat C. Daw, Joanna G. Fernandez, Neeta Somaiah, Gregory Ravizzini, Kamalesh Sankhala, Sant P. Chawla, Cindy L. Schwartz, David S. Hong; Eric Rohren. Safety and Feasibility of Alpha Particle Radium-223 Dichloride Therapy in High Risk Osteosarcoma: A Phase 1 Dose Escalation Trial. Connective Tissue Oncology Society (CTOS) Annual Meeting 2015, 2015.
60. Brian Samuels, MD, Sant P. Chawla, Neeta Somaiah, Arthur Staddon, Keith M. Skubitz, Kevin Mulvey, Mohammed Milhem, Pamela Kaiser, David Portnoy, Dennis Priebat, Mark Walker, Edward Stepanski. Phase II Study of Pazopanib in Patients with Advanced Intermediate of High-Grade Liposarcoma. Connective Tissue Oncology Society (CTOS) Annual Meeting 2015, 2015.
61. N. Somaiah, E. Gilbert, A. P. Conley, A. M. Zarzour, S. Patel, R. S. Benjamin, P. Bhosle, H. Lin, K. Watson, B. Feig, K.E. Torres, C. Roland. PET/CT Imaging Might Be Superior to Percutaneous Biopsy in Identifying Dedifferentiation in Patients with Well-Differentiated (WDLS)/Dediffer. Connective Tissue Oncology Society (CTOS) Annual Meeting 2015, 2015.
62. Neeta Somaiah, Matthew Stephen Block, Joseph W. Kim, Geoffrey Shapiro, Patrick Hwu, Joseph Paul Eder, Robin Lewis Jones, Sacha Gnjatic, Hailing Lu, Frank James Hsu, Seth Pollack. Phase I, first-in-human trial of LV305 in patients with advanced or metastatic cancer expressing NY-ESO-1. J Clin Oncol, ASCO Annual Meeting 2015(33), 2015.
63. Neeta Somaiah, Hannah Beird, Kenna Rael Shaw, Wei-Lien Wang, Anthony Paul Conley, Vinod Ravi, Keila E Torres, Davis Ingram, Christina Lynn Roland, Vivek Subbiah, Barry W. Feig, Alexander J. F. Lazar, Robert S. Benjamin, Shreyaskumar Patel, Patrick Hwu, Andrew Futreal, Funda Meric-Bernstam, David S. Hong. Targeted next generation sequencing in well-differentiated/dedifferentiated liposarcoma (WD/DD LPS): Multiple gene amplifications but few mutations. J Clin Oncol, ASCO Annual Meeting 2015(33), 2015.
64. Ranee Mehra, Aruna Turaka, Joshua E. Meyer, Brian L. Egleston, Tawee Tanvetyanon, Mary Colleen Pinder, Thomas J. Dilling, Charles C. Williams, Jhanelle Elaine Gray, Keisuke Shirai, R. Katherine Alpaugh, Debbie Riordan, Neeta Somaiah, Prashant C. Shah, Walter Joseph Scott, George R. Simon, Hossein Borghaei. Phase I study of vorinostat with concurrent chemoradiotherapy (CRT) for locally advanced non-squamous non-small cell lung cancer (NSCLC). J Clin Oncol, ASCO Annual Meeting 2015(33), 2015.
65. Andrew J. Wagner, Udai Banerji, Amit Mahipal, Neeta Somaiah, Heather Anne Hirsch, Craig Fancourt, Amy Levonas, Raymond Lam, Amy Meister, Ramon Karmel Kemp, Clayton Knox, Shelonitda Rose, David S. Hong. A phase I trial of the human double minute 2 (HDM2) inhibitor MK-8242 in patients (pts) with advanced solid tumors. J Clin Oncol, ASCO Annual Meeting 2015(33), 2015.
66. Saroj Vadhan-Raj, Vinod Ravi, Xiao Zhou, Dejka M. Araujo, Neeta Somaiah, Anthony Paul Conley, Mary Daniel, Robert S. Benjamin, Shreyaskumar Patel, Ivan Spasojevic. Effects of fosaprepitan (Fosa) on ifosfamide (Ifex) metabolism in sarcoma patients (pts) receiving multi-day chemotherapy (CT) regimen on doxorubicin (Dox) and Ifex (AI): Randomized, cross-over study. J Clin Oncol, ASCO Annual Meeting 2015(33), 2015.
67. Anthony Paul Conley, Robert L Satcher, Wei-Lien Wang, Alexander J. F. Lazar, Patricia S Fox, Patrick P. Lin, Bryan Moon, Justin E Bird, Dejka M. Araujo, Vinod Ravi, Neeta Somaiah, Shreyaskumar Patel, Robert S. Benjamin, Valerae O. Lewis. Clinical characteristics and treatment outcomes of clear cell chondrosarcomas: MD Anderson Cancer Center Series. J Clin Oncol, ASCO Annual Meeting 2015(33), 2015.
68. Michael Wagner, Kenneth R. Hess, David S. Hong, Chad Tang, Aung Naing, Siqing Fu, Filip Janku, Sarina Anne Piha-Paul, Ralph Zinner, Jennifer J. Wheler, Apostolia Maria Tsimberidou, Shreyaskumar Patel, Neeta Somaiah, Vinod Ravi, Robert S. Benjamin, Funda Meric-Bernstam, Vivek Subbiah. Validation of the Royal Marsden Hospital (RMH) prognostic score in 100 patients with advanced sarcoma enrolled in early phase clinical trials at a major cancer center. J Clin Oncol, ASCO Annual Meeting 2015(33), 2015.
69. Conley AP, Wang W-L, Ravi V, Somaiah N, Subbiah V, Benjamin RS, Patel S. Clinical Outcomes for patients with metastatic, malignant granular cell tumors treated with systemic therapies. Connective Tissue Oncology Society (CTOS) Berlin, 2014.
70. Ravi V, Ramesh N, Patnana M, Conley AP, Somaiah N, Lazar AJ, Araujo D, Torres KE, Ali S, Miller VA, Benjamin RS. Targeted sequencing of leiomyosarcomas in the clinic: Potential for target identification. Connective Tissue Oncology Society (CTOS) Berlin, 2014.
71. Conley AP, Somaiah N, Torres KE, Benjamin RS, Wang W-L, Hwu P, Patel S, Rohren E.. Predicting survival using FDG pet responses in patients with unclassified sarcoma. Connective Tissue Oncology Society (CTOS) Berlin, 2014.
72. Subbiah V, Patel S, Benjamin RS, Agarwal R, Janku F, Ludwig J, Anderson PM, Araujo D, Ravi V, Conley AP, Somaiah N, Naing A, Hong DS, Meric-Bernstam F. Targeted-Based therapeutic matching in early-phase clinical trials in patients with advanced sarcoma. Connective Tissue Oncology Society (CTOS) Berlin, 2014.
73. Livingston JA, Bugano D, Madewell J, Wang W-L, Conley AP, Ravi V, Araujo D, Tseng WW, Feig B, Torres KE, Benjamin RS, Somaiah, N. Assessing chemotherapy benefit in well-differentiated/De-differentiated liposarcoma. Connective Tissue Oncology Society (CTOS) Berlin, 2014.
74. Somaiah N, Pollack SM, Wei-W, Araujo D, Amaria RN, Mittendon EA, Conley AP, Ravi V, Subbiah V, Benjamin RS, Patel S, Kenney R, Hsu F, Hwu P, Jones RL, Shapiro G, Kim JW, Block MM. Evaluating the safety and immunogenicity of IS-LV305, a third generation lentiviral vaccine in patients with ny-eso-1 positive malignancies. Connective Tissue Oncology Society (CTOS) Berlin, 2014.
75. Neeta Somaiah, Diogo Bugano Diniz Gomes, John E Madewell, Wei-Lien Wang, Anthony Paul Conley, Vinod Ravi, Dejka M. Araujo, Joseph A. Ludwig, Robert S. Benjamin, Shreyaskumar Patel. Defining the chemotherapy (CT) response in well-differentiated (WD) and dedifferentiated (DD) liposarcomas (LPS) of the retroperitoneum (RP): A tertiary referral cancer center experience. American Society of Clinical Oncology (ASCO) Conference 2014, 2014.
76. Vivek Subbiah, Rishi Agarwal, Filip Janku, Apostolia Maria Tsimberidou, Shreyaskumar Patel, Robert S. Benjamin, Joseph A. Ludwig, Peter Meade Anderson, Dejka M. Araujo, Vinod Ravi, Anthony Paul Conley, Neeta Somaiah, Wei-Lien Wang, Aung Naing, Ralph Zinner, David S. Hong, Funda Meric-Bernstam. Diversity and heterogeneity in molecular analysis of advanced sarcomas: The clinical, regulatory, and financial challenge for drug development and precision medicine. J Clin Oncol, ASCO Annual Meeting 2014(32:5s), 2014.
77. Saroj Vadhan-Raj, Xiao Zhou, Dejka M. Araujo, Neeta Somaiah, Anthony Paul Conley, Vinod Ravi, Mary Daniel, Robert S. Benjamin, Shreyaskumar Patel. Effects of fosaprepitant (Fosa) administered as single dose versus two doses, on nausea/vomiting (N/V) in patients receiving multiday chemotherapy (CT) with a highly emetogenic regimen of doxorubicin and ifosafamide (AI): Randomized cross-over study. J Clin Oncol, ASCO Annual Meeting 2014(32:5s), 2014.
78. Shadia Ibrahim Jalal, Nasser H. Hanna, Robin Zon, Gregory A. Masters, Hossein Borghaei, Karuna Koneru, Sunil S. Badve, Nagendra K Prasad, Neeta Somaiah, Jingwei Wu, Zhangsheng Yu, Lawrence H. Einhorn. Final results of a phase I study of amrubicin and cyclophosphamide in patients with advanced solid organ malignancies: HOG LUN 07-130. J Clin Oncol, ASCO Annual Meeting 2014(32:5s), 2014.
79. Vinod Ravi, Naveen Ramesh, Madhavi Patnana, Anthony Paul Conley, Neeta Somaiah, Maria Alejandra Zarzour, Davis Ingram, Latasha Little, Alexei Protopopov, Alexander J. F. Lazar, Dejka M. Araujo, Keila E Torres, Shreyaskumar Patel, Jianhua Zhang, Siraj M. Ali, Vincent A. Miller, Philip J. Stephens, Robert S. Benjamin, Patrick Hwu, Andrew Futreal. Whole-exome and targeted sequencing of angiosarcomas: Target identification and treatment implications. J Clin Oncol, ASCO Annual Meeting 2014(32:5s), 2014.
80. Somaiah N, Ingram D, Liu J, Bolshakov S, de Graaff M, Szuhai K, Aman P, Toress KE, Lev D, Nielsen T, Bovee J, Lazar AJ. Establishment and characterization of a new human myxoid liposarcoma cell line (DL-221) with the FUS-DDIT3 translocation. Connective Tissue Oncology Society (CTOS) 18th Annual Meeting, 2013.
81. Tseng WWW, Madewell J, Wang W, Somaiah N, Lazar A, Ghadimi M, Hoffman A, Pisters P, Lev D, Pollock R.. Analysis of locoregional disease patterns as a guide to the extent of resection in well differentiated and dedifferentiated retroperitoneal liposarcoma. Connective Tissue Oncology Society (CTOS) 18th Annual Meeting, 2013.
82. Ravi V, Ramesh N, Somaiah N, Leja M, Conley P, Ludwig J, Araujo D, Taylor S, Torres K, Wang W, Hunt K, Reardon M, Benjamin R, Patel S. Cardiac angiosarcoma: Clinical features and treatment outcomes. Connective Tissue Oncology Society (CTOS) 18th Annual Meeting, 2013.
83. Tseng WW, Malu S, Zhang M, Somaiah N, Ingram D, Lev DC, Pollock R, Lizee G, Radvanyi L, Hwu P. A feasibility study and trial proposal of immune checkpoint blockage in well and dedifferentiated retroperitoneal liposarcoma. Connective Tissue Oncology Society (CTOS) 18th Annual Meeting, 2013.
84. Somaiah N, Raj S, Gupta R, Ravi V, Conley T, Araujo D, Benjamin R, Patel S, Banchs J, Vadhan-Raj S. Low incidence of cardiotoxicity noted with high-dose doxorubicin (A) at 90mg/m2/cycle given as a continuous infusion. Connective Tissue Oncology Society (CTOS) 18th Annual Meeting (#1764432), 2013.
85. Tap WD, Van Tine BA, Elias AD, Livingston MB, Agulnik M, Cooney MM, Chmielowski B, Brenner AJ, Pennock GK, Somaiah N, Dang LH, Tian GG, Jones RL, Okuno SH, Loizos N, Nippgen J, Schwarts GK. A phase lb/ll study evaluating the efficacy of doxorubicin (D) with or without a human anti-PDGFRa monoclonal antibody olaratumab (IMC-3G3) in the treatment of advanced soft tissue sarcoma (STS). J Clin Oncol, ASCO Annual Meeting 2012, 2012.
86. Cauchi C, Somaiah N, Engstrom PF, Litwin S, Lopez M, Lee J, Davey M, Bove B, Godwin AK, von Mehren M. Evaluation of nilotinib in advanced GIST previously treated with imatinib mesylate and sunitinib. J Clin Oncol, ASCO Annual Meeting 2010(28:15s), 2010.

Book Chapters

1. Thirasastr P, Brahmi M, Dufresne A, Blay JY, Somaiah N. New Drug Approvals in the Last 5 Years for Sarcoma. In: Surgical Oncology Clinics, 2022.
2. Parkes A, Somaiah N. Chapter 8, Leiomyosarcoma. In: Sarcomas: Evidence-Based Diagnosis and Management, 2020.
3. Somaiah N, Gupta R, Patel S. Chapter on Gastrointestinal Stromal Tumors. In: Textbook of GI Oncology, 2017.
4. Somaiah N. Gastrointestinal Stromal Tumors: Clinical Care Options In Practice. In: Online book chapter, 2016.
5. Somaiah N. Gastrointestinal Stromal Tumors: Clinical Care Options In Practice. In: Online book chapter, 2014.
6. Somaiah N, Patel S. Soft Tissue Sarcoma. In: Cancer Consult: Expertise for Clinical Practice. John Wiley and Sons, 2014.
7. Somaiah N. Gastrointestinal Stromal Tumors: Clinical Care Options In Practice. In: Online book chapter, 2013.
8. Somaiah N. Gastrointestinal Stromal Tumors: Clinical Care Options In Practice. In: Online book chapter, 2012.
9. Somaiah N, von Mehren M. The Role of Tyrosine Kinase Inhibitors in the Treatment of Gastrointestinal Stromal Tumors. In: Medscape, 2008.